Stocks
X4 Pharmaceuticals, Inc.XFOR
NASDAQHealthcareBiotechnology$3.02
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for rare and orphan diseases, with a focus on treatments for chronic neutropenia. Its lead candidate, mavorixafor, is in late-stage development and has shown promise in reducing infection risk in patients with WHIM syndrome. Investors track X4 for its potential first-in-class oral therapy and upcoming regulatory milestones.
52W Range: $2.43-$4.83
Congressional Interest in X4 Pharmaceuticals, Inc. (XFOR)
No congressional trades have been disclosed for X4 Pharmaceuticals, Inc. (XFOR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading XFOR?
No congressional trades found for this stock.